Real-Life Tolerability and Effectiveness of Adalimumab Biosimilar in Rheumatoid Arthritis: ASPIRE Registry Data
Authors:
Open Access
- 28 June 2019
- journal article
- research article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 6 (3) , 451-459
Abstract
Introduction The TNF-α blocker adalimumab is a well-proven therapy for rheumatoid arthritis (RA). A biosimilar adalimumab (ZRC-3197; Exemptia™), a ‘fingerprint match’ to reference adalimumab, has been approved for prescription in India since 2014. Here, we report on the effectiveness and tolerability of this biosimilar adalimumab (bADA) from the Adalimumab Biosimilar Patient Registry [ASPIRE; ISRCTN16838474], which contains data from real-life RA patients from India. Methods ASPIRE is a post-marketing, observational registry that evaluates real-world experience across multiple centres in India. Patients with moderate to severe RA who were prescribed bADA 40 mg subcutaneously every fortnight were enrolled. Patients with complete data available until 24 weeks of bADA treatment were extracted and analyzed for standard disease activity measures and reported adverse events. Results The registry included 149 patients with RA who had a median age of 41 (22–67) years; 65% of the patients were female. Disease outcome measures, i.e. ESR, DAS-ESR and VAS-pain scores, showed gradual and significant decreases (p < 0.0001 for all) in 73 analyzable patients who received 24 weeks of bADA therapy. ACR20, ACR50 and ACR70 responses were achieved in 48%, 48% and 34% of patients after 24 weeks of therapy, respectively, and about 58% and 15% of patients were moderate and good EULAR responders, respectively. Physician and patient ratings for the overall global assessment of efficacy and tolerability were ‘good’ to ‘excellent’ for the majority of the patients (≥ 96%). No new safety signals were observed when analyzing this registry data. Conclusion Real-life data from this post-marketing observational analysis demonstrate the clinical effectiveness and tolerability of 24 weeks of adalimumab biosimilar therapy in Indian patients with RA. This report also reflects upon the treatment strategies and prescription patterns for such therapies in Indian clinical practice. Trial Registration ISRCTN16838474. Funding Cadila Healthcare Limited, India.Keywords
This publication has 18 references indexed in Scilit:
- The road from development to approval: evaluating the body of evidence to confirm biosimilarityRheumatology, 2017
- A practical guide about biosimilar data for health care providers treating inflammatory diseasesBiologics: Targets and Therapy, 2017
- The changing landscape of biosimilars in rheumatologyAnnals of the Rheumatic Diseases, 2016
- Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatologyRheumatology International, 2016
- A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia;ZRC‐3197) and adalimumab (Humira) in patients with rheumatoid arthritisInternational Journal of Rheumatic Diseases, 2015
- Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practiceRheumatology, 2007
- Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failedAnnals of the Rheumatic Diseases, 2004
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- Adalimumab (a fully human anti-tumour necrosis factor α monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trialsAnnals of the Rheumatic Diseases, 2002
- Cytokine Pathways and Joint Inflammation in Rheumatoid ArthritisNew England Journal of Medicine, 2001